Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Published:2022-03 Issue: Volume:45 Page:101323
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Pitisuttithum Punnee,Luvira Viravarn,Lawpoolsri Saranath,Muangnoicharoen Sant,Kamolratanakul Supitcha,Sivakorn Chaisith,Narakorn Piengthong,Surichan Somchaiya,Prangpratanporn Sumalee,Puksuriwong Suttida,Lamola Steven,Mercer Laina D.^ORCID,Raghunandan Rama,Sun Weina^ORCID,Liu Yonghong,Carreño Juan Manuel,Scharf Rami,Phumratanaprapin Weerapong,Amanat Fatima,Gagnon Luc,Hsieh Ching-Lin,Kaweepornpoj Ruangchai,Khan Sarwat,Lal Manjari,McCroskery Stephen,McLellan Jason,Mena Ignacio,Meseck Marcia,Phonrat Benjaluck,Sabmee Yupa,Singchareon Ratsamikorn,Slamanig Stefan,Suthepakul Nava,Tcheou Johnstone^ORCID,Thantamnu Narumon,Theerasurakarn Sompone,Tran Steven,Vilasmongkolchai Thanakrit,White Jessica A,Bhardwaj Nina,Garcia-Sastre Adolfo,Palese Peter,Krammer Florian,Poopipatpol Kittisak,Wirachwong Ponthip,Hjorth Richard,Innis Bruce L^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. (WHO) WHO. https://www.who.int/director-general/speeches/detail/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021. 2021.

2. Global production capacity of seasonal and pandemic influenza vaccines in 2019;Sparrow;Vaccine,2021

3. A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine;Sun;Vaccines (Basel),2020

4. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes;Hsieh;Science,2020

5. A Newcastle disease virus- expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses;Sun;Nat Commun,2021

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study;Vaccine: X;2024-10

2. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22

3. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice;eBioMedicine;2024-07

4. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges;npj Vaccines;2024-05-23

5. UV-Inactivated rVSV-M2e-Based Influenza Vaccine Protected against the H1N1 Influenza Challenge;Frontiers in Bioscience-Landmark;2024-05-20